A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy
Nathalie Goemans, Yasuhiro Takeshima(Hyogo University), E. Niks(Leiden University Medical Center), David Feder, Janbernd Kirschner(University of Freiburg), Magnhild Rasmussen(Oslo University Hospital), Giles Campion(BioMarin (United States)), Salmo Raskin(Universidade Positivo), Erik Henricson(UC Davis Health), Zhengning Lin(BioMarin (United States)), Karin Kleinsteuber(BioMarin (United States)), Ágnes Herczegfalvi, Susanne X. Wang(BioMarin (United States)), Yuh‐Jyh Jong(National Yang Ming Chiao Tung University), Giacomo P. Comi(University of Milan), Isabelle Desguerre(ASTER), Kathryn Selby(University of British Columbia), J. Colomer Oferil(Research Triangle Park Foundation), Eugenio Mercuri(Università Cattolica del Sacro Cuore), Alessandra Ferlini(University of Ferrara), Ricardo Erazo Torricelli, B. Chabrol(Hôpital d'Enfants), Martin Kudr, Yann Péréon(European Organisation for Rare Diseases), Marika Pane(Università Cattolica del Sacro Cuore), Abelardo Araújo, Raúl G. Escobar, Enrico Bertini(Bambino Gesù Children's Hospital), Jong‐Hee Chae(Seoul National University), Guy D’Anjou(Université de Montréal), Hirofumi Komaki(National Center of Neurology and Psychiatry), Е. Д. Белоусова(Pirogov Russian National Research Medical University), Craig M. McDonald(University of California Davis Medical Center), Afrodite Lourbakos(BioMarin (United States)), U.C. Reed, Cláudia Ferreira da Rosa Sobreira(Universidade de São Paulo), Shigemi Kimura(Kumamoto University), Anna Kostera‐Pruszczyk(Medical University of Warsaw), Samuel Ignacio Pascual Pascual(Hospital Universitario La Paz), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Concetta Palermo(Università Cattolica del Sacro Cuore), Wolfgang Mueller‐Felber(BioMarin (United States)), Ulrike Schara, Peter Born, Alberto Dubrovsky, J. Cuisset, John E. Kraus(Research Triangle Park Foundation), Craig Campbell(Children's Hospital of Western Ontario), Katsuhisa Ogata(BioMarin (United States)), Claude Cancés(Hôpital des Enfants)
Cited by 128
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820